Do GLP-1s reduce alcohol cravings? What the trials found

Reviewed 26 sourcesPublished by PepVault

Do GLP-1s cut alcohol cravings? What the semaglutide, exenatide and dulaglutide trials found, the health-record data, the trials running now, and the labels.

Grey-curled woman in a rust dress laughs at a cafe table with sparkling water and a salad
Last reviewed
Sources
26
Questions
8
Compounds
7

The short answer

In the trials so far, mostly yes. As of November 2026, three randomized semaglutide trials found less craving or less heavy drinking than placebo; the largest, in 108 adults with obesity over 26 weeks, cut heavy drinking days by 13.7 percentage points more than placebo. An earlier exenatide trial missed its main goal. No GLP-1 is approved for alcohol use, so treatment stays a prescriber's call.

Every number checked at its primary source · · 26 sources · How we research

Evidence: Six placebo-controlled trials in people who drink heavily (four semaglutide or exenatide trials in alcohol use disorder, one dulaglutide secondary analysis, one company-reported pemvidutide topline), large health-record studies that show association rather than cause, a meta-analysis, surveys and a case series, and rodent and monkey studies for the brain pathway; no phase 3 result yet.

Grey-curled woman in a rust dress laughs at a cafe table with sparkling water and a salad

Why would a weight-loss drug change drinking?

Alcohol feels rewarding because it releases dopamine, a chemical messenger, in the brain's reward circuit, a pathway that runs into the nucleus accumbens, a small hub deep in the brain that tags things as worth repeating. GLP-1 drugs act on a gut hormone's receptor, and those receptors also sit in this circuit. When the drug reaches them, a drink pays out less: in animals, alcohol releases less dopamine there.

The animal work shows each step. In rats, a fluorescently tagged copy of semaglutide reached the nucleus accumbens, and semaglutide cut alcohol intake and blocked relapse-like drinking in males and females; in mice it stopped alcohol from raising dopamine there12. Semaglutide also cut binge-like and dependence-driven drinking in mice and rats13, and in 20 alcohol-preferring male vervet monkeys it lowered how much they chose to drink, with no vomiting and no change in water intake14. Tirzepatide, which also acts on the receptor for a second gut hormone, GIP, did the same in rodents, including blocking relapse-like drinking15. These are animal results.

The human evidence points at the same circuit. In the exenatide trial below, brain scans showed a weaker response to pictures of alcohol in the ventral striatum, the region that holds the nucleus accumbens, than on placebo4. The appetite side of the same story, the quieting of food thoughts, has its own guide: Food noise on a GLP-1.

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

The daily check-in on PepVault's Today screen has a note field: write the day's drinks there. Each note is saved to its day, and PepTalk reads your notes beside the doses you logged.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What did the randomized trials find?

Six placebo-controlled trials have reported drinking results. A heavy drinking day means 4 or more drinks for a woman or 5 or more for a man in the 2025 US trial2; the Danish trials counted it in grams of alcohol1. All but the pemvidutide trial have been peer reviewed.

TrialWho and how longDrug and doseMain result against placebo
Klausen 2022, Denmark127 adults seeking treatment for alcohol use disorder, 26 weeks, with talk therapyExenatide 2 mg weeklyNo significant drop in heavy drinking days (the main goal); fewer heavy drinking days and less total alcohol in the subgroup with a BMI over 30, an exploratory finding4
Probst 2023, Switzerland151 drinkers in a stop-smoking trial, 12 weeksDulaglutide 0.75 mg the first week, then 1.5 mg weekly29% less alcohol drunk at week 125
Hendershot 2025, US48 adults with alcohol use disorder not seeking treatment, 9 weeksSemaglutide injection, 0.25 mg weekly for 4 weeks, then 0.5 mg (1.0 mg in the last week)Less alcohol drunk in a lab drinking session (the main goal); fewer drinks per drinking day and less weekly craving; no change in how many days people drank2
Schacht 2026, US50 adults with moderate to severe alcohol use disorder seeking treatment, 8 weeksOral semaglutide, 3 mg then 7 mg dailyNo change in lab craving (the main goal) or drinks per day; fewer heavy drinking days, fewer drinks per drinking day, less everyday craving3
Klausen 2026, Denmark (Lancet)108 adults with moderate to severe alcohol use disorder and obesity, 26 weeks, with talk therapySemaglutide up to 2.4 mg weeklyShare of heavy drinking days down 41.1 percentage points from baseline against 26.4 on placebo, a 13.7-point difference (the main goal)1
RECLAIM 2026, US (company topline)About 100 adults with alcohol use disorder and a BMI over 25, 24 weeksPemvidutide 2.4 mg weekly (GLP-1 plus glucagon)Heavy drinking days down 4.20 a week against 2.75; 64.4% against 34.8% dropped two drinking-risk levels6

In both US semaglutide trials the clearest change was in how much people drank once they started: drinks per drinking day fell, while the number of drinking days2 and drinks per calendar day23 did not change significantly. The clearest result so far came in a 26-week trial at the full weight-loss dose, in people with obesity1, and the exenatide trial's only clear signal was in its subgroup with obesity too4.

Exenatide is an older GLP-1 drug, and even with the miss its trial saw a calmer reward response on brain scans and less dopamine transporter, a marker of dopamine signaling, than placebo4. Our page on that trial has the detail: Exenatide for alcohol use disorder: 26-week trial results.

What do the health-record studies show?

Large records studies point the same way, across millions of patients. They show an association, not proof: people who are prescribed a GLP-1 may differ from people who are not.

  • US, 83,825 patients with obesity: semaglutide was linked to a 50-56% lower risk of a first or repeat alcohol use disorder diagnosis over 12 months than other weight-loss drugs; the pattern held in 598,803 patients with type 2 diabetes7.
  • Sweden, 227,866 people with alcohol use disorder: during the months they took semaglutide, their risk of an alcohol-related hospital stay was 36% lower than when they did not (hazard ratio 0.64), and 28% lower on liraglutide; the approved alcohol medicines together lowered it by about 2%8.
  • US, 817,309 patients with alcohol use disorder: a GLP-1 or GIP/GLP-1 prescription went with half the rate of alcohol intoxication9.
  • US veterans: drinking scores fell more on a GLP-1 than on no drug or on DPP-4 inhibitors, a different diabetes pill, most of all in people who drank heavily at the start10.

A 2025 meta-analysis pooled 14 studies, 4 randomized and 10 observational, and found drinking-problem scores (the AUDIT, scored 0 to 40) lower by 7.8 points on average with a GLP-1, with wide variation between studies11.

Does it work if you don't have obesity?

That is the open question. The Lancet trial enrolled only people with a BMI of 30 or more1, and exenatide's benefit showed only in that group4. The 2025 US trial set its floor at a BMI of 23 and averaged 32; 21 of its 48 participants had a BMI under 30, and the authors did not report a separate result for them2. The pemvidutide trial took people with a BMI over 256. The records studies are mostly people with obesity or type 2 diabetes, because those are the people who get these drugs78.

No GLP-1 drug is approved for alcohol use. Wegovy's label lists weight, heart and liver uses, and Zepbound's weight and sleep apnea; neither lists drinking1819. The US has three approved medicines for alcohol use disorder: naltrexone, acamprosate and disulfiram20.

Which trials are running now?

As of November 2026, ClinicalTrials.gov lists larger and longer trials than any so far, including the first phase 3 trials, the last stage before a drug company can ask for approval.

TrialDrugSize and lengthStatus (registry, November 2026)
Two Eli Lilly phase 3 trials (NCT07219966, NCT07219953)Brenipatide, an investigational injection under the skin; the registry does not name its drug classAbout 1,100 people each, about 56 weeks in the studyRecruiting2223
US Veterans Affairs phase 3 (NCT07218354)Semaglutide up to 2.4 mg weekly622 veterans, 24 weeks of treatmentRecruiting24
Eli Lilly phase 2 (NCT06817356)Mazdutide (GLP-1 plus glucagon)308 peopleCompleted; no results posted25
University of Southern California phase 2 (NCT06994338)Tirzepatide42 adults with overweight or obesity, 8 weeksRecruiting, by a record last updated in October 202526

What do people on a GLP-1 report about drinking?

These are reports, not trials. Researchers who sorted 1,580 alcohol-related Reddit posts about semaglutide and tirzepatide with a machine-learning tool found that 72% described less craving, less drinking or other negative effects of drinking, such as feeling sick or full16. In the same study, 153 drinkers with obesity on either drug reported fewer drinks per occasion, lower odds of binge drinking and weaker buzz and sedation from alcohol than before starting and than people not on the drugs16. In a chart review of 6 people with a positive alcohol screen who started semaglutide for weight loss, every one improved, by 9.5 AUDIT points on average17.

Commonly reported: the second and third drink losing their pull, a glass left half full, feeling full or a little queasy after one drink, and nights out ending earlier without any effort to cut back.

Is it safe to drink alcohol on a GLP-1?

Neither the Wegovy nor the Zepbound label lists alcohol as an interaction1819. In the 2025 semaglutide trial, people drank in a supervised lab session on the drug: they drank less and reached a lower peak breath alcohol, with no serious side effects and no harmful interactions with alcohol recorded2. Across the trials the side effects were the usual ones for these drugs, mostly mild to moderate stomach effects such as nausea14; in the pemvidutide trial, nausea came in 44% against 24% on placebo6.

How can you track your drinking on a GLP-1?

The trials measured drinking with a day-by-day calendar of drinks, and the same record works at home. It shows your prescriber what changed, and when, around each dose step.

  1. Count in standard drinks: one US standard drink is about 14 g of alcohol, which is a 12-ounce beer at 5%, a 5-ounce glass of wine at 12% or a 1.5-ounce shot of spirits at 40%21.
  2. Write down each day's total, including the days you drink nothing.
  3. Mark the heavy days: 4 or more drinks for a woman, 5 or more for a man2.
  4. Note the day of each injection and every dose change, so a shift can be lined up against the dose.
  5. Once a month, count your heavy days and your drinks per drinking day, the two numbers that moved most in the trials23, and bring them to your next appointment.

The daily check-in on PepVault's Today screen has a note field: write the day's drinks there. Each note is saved to its day, and PepTalk reads your notes beside the doses you logged. Log it in PepVault

When to get help If you drink heavily most days, speak with a doctor before cutting down quickly: after long heavy drinking, withdrawal can be dangerous, and a doctor can plan it safely20.

Track it in the app

Sources

  1. Klausen MK et al. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial. Lancet. 2026. PubMed 42070571
  2. Hendershot CS et al. Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry. 2025. PubMed 39937469
  3. Schacht JP et al. Oral semaglutide for alcohol use disorder: a randomized clinical trial. Am J Psychiatry. 2026. PubMed 42522065
  4. Klausen MK et al. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight. 2022. PubMed 36066977
  5. Probst L et al. Effects of dulaglutide on alcohol consumption during smoking cessation. JCI Insight. 2023. PubMed 37991022
  6. Altimmune. Altimmune announces positive topline results from RECLAIM phase 2 trial of pemvidutide in alcohol use disorder. Press release, July 28, 2026. biospace.com
  7. Wang W et al. Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. Nat Commun. 2024. PubMed 38806481
  8. Lähteenvuo M et al. Repurposing semaglutide and liraglutide for alcohol use disorder. JAMA Psychiatry. 2025. PubMed 39535805
  9. Qeadan F et al. The association between glucose-dependent insulinotropic polypeptide and/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders. Addiction. 2025. PubMed 39415416
  10. Farokhnia M et al. Glucagon-like peptide-1 receptor agonists, but not dipeptidyl peptidase-4 inhibitors, reduce alcohol intake. J Clin Invest. 2025. PubMed 40048376
  11. Eshraghi R et al. Effects of glucagon-like peptide-1 receptor agonists on alcohol consumption: a systematic review and meta-analysis. EClinicalMedicine. 2025. PubMed 41324012
  12. Aranäs C et al. Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats. EBioMedicine. 2023. PubMed 37295046
  13. Chuong V et al. The GLP-1 analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission. JCI Insight. 2023. PubMed 37192005
  14. Fink-Jensen A et al. Effect of the GLP-1 receptor agonist semaglutide on alcohol consumption in alcohol-preferring male vervet monkeys. Psychopharmacology (Berl). 2025. PubMed 38884652
  15. Edvardsson CE et al. Tirzepatide reduces alcohol drinking and relapse-like behaviours in rodents. EBioMedicine. 2026. PubMed 41506148
  16. Quddos F et al. Semaglutide and tirzepatide reduce alcohol consumption in individuals with obesity. Sci Rep. 2023. PubMed 38017205
  17. Richards JR et al. Significant decrease in alcohol use disorder symptoms secondary to semaglutide therapy for weight loss: a case series. J Clin Psychiatry. 2023. PubMed 38019594
  18. Novo Nordisk. WEGOVY (semaglutide) injection and tablets, prescribing information. DailyMed, revised June 2026. dailymed.nlm.nih.gov
  19. Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, prescribing information. DailyMed, revised August 2026. dailymed.nlm.nih.gov
  20. National Institute on Alcohol Abuse and Alcoholism. Treatment for alcohol problems: finding and getting help. Updated February 2025. niaaa.nih.gov
  21. National Institute on Alcohol Abuse and Alcoholism. What is a standard drink? Updated December 2025. niaaa.nih.gov
  22. ClinicalTrials.gov. NCT07219966: A study of brenipatide in participants with moderate-to-severe alcohol use disorder (Eli Lilly). Last updated October 7, 2026. clinicaltrials.gov
  23. ClinicalTrials.gov. NCT07219953: A study of brenipatide in participants with alcohol use disorder (Eli Lilly). Last updated November 4, 2026. clinicaltrials.gov
  24. ClinicalTrials.gov. NCT07218354: Cessation or reduction of alcohol consumption in veterans: a randomized controlled trial of semaglutide (VA Office of Research and Development). Last updated September 21, 2026. clinicaltrials.gov
  25. ClinicalTrials.gov. NCT06817356: A study to evaluate mazdutide compared with placebo in participants with alcohol use disorder (Eli Lilly). Last updated July 16, 2026. clinicaltrials.gov
  26. ClinicalTrials.gov. NCT06994338: Tirzepatide for alcohol use disorder (University of Southern California). Last updated October 14, 2025. clinicaltrials.gov

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo